ArticleCureus2026
Assessment of the Prevalence and Characteristics of Hip Involvement in Spondyloarthritis: Results From a Rheumatology Outpatient Center.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimHip involvement is a well-recognized feature of axial spondyloarthritis (AS). This study aimed to assess the prevalence of hip involvement and its relationship with both symptomatic and structural severity in a cohort of AS patients treated in an outpatient rheumatology clinic.
methodsThis retrospective, single-center study was conducted from 2019 to 2023 and included confirmed AS patients. Hip involvement was defined as hip pain related to AS-driven inflammation, confirmed by radiographic imaging (Bath Ankylosing Spondylitis Radiology Hip Index, or BASRI, score of ≥2). Demographic data and parameters of both symptomatic and structural severity were collected. The risk of hip involvement based on disease duration was evaluated using Kaplan-Meier analysis.
resultsAmong 137 AS patients, 89 were men (65.0%), and 48 (35.0%) were women. The mean age was 42.2 years (SD ±14, range: 18-76), and the mean disease duration was 7.5 years (SD ±9.1, range: 0.5-38). Radiographic evidence of hip involvement was present in 19 patients (13.9%): unilateral in 9 patients (6.6%) and bilateral in 10 patients (7.3%). Hip involvement was more common in men, those with longer disease duration, and those with a higher incidence of uveitis. Patients with hip involvement exhibited higher symptomatic (Bath Ankylosing Spondylitis Disease Activity Index, or BASDAI, and Ankylosing Spondylitis Disease Activity Score, or ASDAS) and structural (modified Stoke Ankylosing Spondylitis Spine Score, or mSASSS) severity scores. In terms of disease duration, 18.6% of male patients had hip involvement after 10 years, rising to 48.8% after 20 years.
conclusionHip involvement is a frequent manifestation of AS, often presenting bilaterally and associated with longer disease duration and greater disease severity. However, its prevalence appears lower in outpatient settings compared to university hospital series.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.